CD4 and tuberculosis: In univariate analysis, WHO stage 3/4, CD4 count <100 cells/μl, CD4 count 100–349 cells/μl, history of anti-tuberculosis treatment and having side effects were independently associated with non-completion of IPT; participants with WHO stage 3/4 had just over 3-fold increased odds of not completing IPT compared with those in WHO stage 1/2 (odds ratio [OR] 3.13, 95%CI 2.35–4.16).